Literature DB >> 20736939

Outcome in cystic fibrosis liver disease.

Marion Rowland1, Charles G Gallagher, Risteard O'Laoide, Gerard Canny, Annemarie Broderick, Roisin Hayes, Peter Greally, Dubhfeassa Slattery, Leslie Daly, Peter Durie, Billy Bourke.   

Abstract

OBJECTIVES: Evidence suggests that cystic fibrosis liver disease (CFLD) does not affect mortality or morbidity in patients with cystic fibrosis (CF). The importance of gender and age in outcome in CF makes selection of an appropriate comparison group central to the interpretation of any differences in mortality and morbidity in patients with CFLD.
METHODS: This is a 7-year follow-up of 42 children with CFLD and their age- and sex-matched controls. Participants were reviewed clinically, biochemically, and radiologically at follow-up.
RESULTS: Overall, 85% (72 of 84) of the original cohort were included, 36 CFLD participants and 36 CF controls. There was no significant difference in the number of deaths/transplants between groups (7 of 36 (19.4%) CFLD participants, 3 of 36 (8.3%) CF controls). There was a tendency for participants with CFLD to die younger than their respective CF controls. There was no difference in height, weight, body mass index, or pulmonary function between the groups. Nutritional parameters (sum skinfold thickness 31.6 vs. 42.3, P=0.03; mean upper arm fat area 15.08 vs. 10.59, P=0.001; Shwachman score 43.7 vs. 32.1, P=0.001) were worse among CFLD participants than among CF controls. Cystic fibrosis-related diabetes was more common in CFLD participants (11 of 27 (40.7%) vs. 5 of 33 (15.2%), P=0.02). Eight children (22.2%) with evidence of CFLD at baseline had no clinical evidence of liver disease as adults.
CONCLUSIONS: Patients with CFLD have a more severe CF phenotype than do CF patients without liver disease. However, a subgroup of children with CFLD will not manifest clinically significant liver disease as adults.

Entities:  

Mesh:

Year:  2010        PMID: 20736939     DOI: 10.1038/ajg.2010.316

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  21 in total

1.  CFTR dysfunction predisposes to fibrotic liver disease in a murine model.

Authors:  Camilia R Martin; Munir M Zaman; Gyanprakash A Ketwaroo; Abdul Q Bhutta; Emmanuel Coronel; Yury Popov; Detlef Schuppan; Steven D Freedman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-07       Impact factor: 4.052

Review 2.  Cystic fibrosis liver disease: A condition in need of structured transition and continuity of care.

Authors:  Julian Hercun; Fernando Alvarez; Catherine Vincent; Marc Bilodeau
Journal:  Can Liver J       Date:  2019-08-27

3.  Liver disease in cystic fibrosis patients in a tertiary care center in Saudi Arabia.

Authors:  Hanaa Banjar; Najlaa AbdulAziz; Jumana Khader; Firas Ghomraoui; AbdulAziz Alansari; Abdulaziz Al-Hoshan; Sara AlKaf; Wajeeh Aldakheel
Journal:  Int J Pediatr Adolesc Med       Date:  2021-06-22

Review 4.  Interventions for preventing and managing advanced liver disease in cystic fibrosis.

Authors:  Senthil K Palaniappan; Nan Nitra Than; Aung Win Thein; Soe Moe; Indra van Mourik
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

5.  Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis.

Authors:  Daniel H Leung; Wen Ye; Jean P Molleston; Alexander Weymann; Simon Ling; Shruti M Paranjape; Rene Romero; Sara Jane Schwarzenberg; Joseph Palermo; Estella M Alonso; Karen F Murray; Bruce C Marshall; Averell H Sherker; Marilyn J Siegel; Rajesh Krishnamurthy; Roger Harned; Boaz Karmazyn; John C Magee; Michael R Narkewicz
Journal:  J Pediatr       Date:  2015-08-05       Impact factor: 4.406

6.  Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials.

Authors:  Nicole Mayer-Hamblett; Margaret Kloster; Bonnie W Ramsey; Michael R Narkewicz; Lisa Saiman; Christopher H Goss
Journal:  Contemp Clin Trials       Date:  2012-11-29       Impact factor: 2.226

Review 7.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

Review 8.  Cirrhosis and other liver disease in cystic fibrosis.

Authors:  Thomas Flass; Michael R Narkewicz
Journal:  J Cyst Fibros       Date:  2012-12-20       Impact factor: 5.482

Review 9.  Liver disease in cystic fibrosis: an update.

Authors:  Giuseppe Fabio Parisi; Giovanna Di Dio; Chiara Franzonello; Alessia Gennaro; Novella Rotolo; Elena Lionetti; Salvatore Leonardi
Journal:  Hepat Mon       Date:  2013-08-14       Impact factor: 0.660

10.  Etiology and management of hemorrhagic complications of portal hypertension in children.

Authors:  Alejandro Costaguta; Fernando Alvarez
Journal:  Int J Hepatol       Date:  2012-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.